Psychologists in Ocean, NJ Accepting Medicare
7 Psychologists found. Showing 1 - 7
 Dr. William Paul Rosenblatt, ED.D. Psychologist Medicare: Medicare Enrolled Practice Location: 2002 Sunset Ave, Ocean, NJ 07712 Phone: 732-775-2960 Fax: 732-774-0675 |
 Kerri Weiss, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1300 Highway 35, Plaza Iii, Ocean, NJ 07712 Phone: 732-845-1111 |
Dr. Benedict Joseph Trigani, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 26 Mahoras Dr, Ocean, NJ 07712 Phone: 732-695-0818 Fax: 732-698-0810 |
Dr. Harry Kyle Barr Iv, PSY.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 2002 Sunset Ave, Ocean, NJ 07712 Phone: 732-859-6205 Fax: 732-774-0675 |
Dr. Ann Booth, PSY.D Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1757 Raleigh Ct W Apt 99b, Ocean, NJ 07712 Phone: 347-200-2484 |
Dr. Robin Solbach, PSYD Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 41 Eisele Ave, Ocean, NJ 07712 Phone: 540-429-2617 |
Dr. Lynn M. Decapua, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 32 Stonehenge Dr, Ocean, NJ 07712 Phone: 732-922-1570 Fax: 732-922-1570 |
News Archive
Avahan AIDS initiative effective at controlling HIV infections in India
A programme funded by the Bill & Melinda Gates Foundation may have saved around 600,000 people in India from becoming infected with HIV over the course of a decade, according to a new report.
CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule
Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.
FDA approves KALYDECO for people with cystic fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
New tool pinpoints genetic sources of disease
Many diseases are the result of either variations in the genome or reversible chemical changes to DNA, known as the epigenome. New data obtained by Johns Hopkins scientists show a connection between genetic variants and epigenetic information.
Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire iForce.
› Verified 8 days ago
Dentists
Clinical Social Workers
Pharmacists
Counselors
Occupational Therapists
Psychologists